Carvedilol (drug) for liver disease

Not Applicable

• Conditions: Health Condition 1: K768- Other specified diseases of liver

• Registration Number: CTRI/2022/01/039527
• Lead Sponsor: Institute of Liver and Biliary Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1) Patients of ACLF (APASL criteria) - jaundice (serum bilirubin � 5 mg/dL and coagulopathy (INR � 1.5) complicated within 4 weeks by clinical ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease/cirrhosis.

2) Age 18-70 yrs

3) Baseline HVPG � 12 mmHg.

Exclusion Criteria

1) Contraindications to NSBB (heart rate < 65 /min, BP < 110/65 mm Hg, asthma, heart failure),

2) Portal Vein Thrombosis,

3) Hepatocellular carcinoma,

4) HVOTO,

5) HE grades 2-4,

6) NSBB therapy within 5 days,

7) Pregnancy,

8) Lactation,

9) Planned for LT in the next 12 weeks

10) No consent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified